The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma

Mert TOHUMCUOĞLU1,*
Mahmut BÜYÜKŞİMŞEK1,*
İsmail Oğuz KARA1
Derya GÜMÜRDÜLÜ2
Emine BAĞIR2

1 Division of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey
2 Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey

* These authors contributed equally to this work.

ABSTRACT

The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma

Introduction: Mesothelioma is an aggressive tumour that originates in serous surfaces. The primary end point of this study was to investigate the relationship of progression free survival (PFS) and overall survival (OS) with the c-Met, EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expression levels in the tumour tissue of pleural and peritoneal mesothelioma cases.

Materials and Methods: The study included 53 patients diagnosed with mesothelioma between 2005 and 2016. The cases were separated into 2 groups as pleural and peritoneal. The effects on OS and PFS were examined of the c-Met, EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expression levels and also clinicopathological parameters and the treatments given. In the statistical analysis of the data obtained, IBM SPSS vn 20.0 software was used.

Results: Of the 53 patients included in the study, 39 (73.6%) were diagnosed with pleural mesothelioma and 14 (26.4%) with peritoneal mesothelioma. According to the c-Met and mTOR expression, OS and PFS of the peritoneal cases with high expression (2+, 3+) was seen to be significantly better than that of the peritoneal cases with low expression (0, 1+) (p< 0.05). According to the PDGFR expression, OS and PFS of the pleural cases with low expression (0, 1+) was seen to be significantly better than that of the pleural cases with high expression (2+, 3+) (p< 0.05).

Conclusion: The examination of c-MET, PDGFR-alpha and m-TOR expression in the in the tumor tissue of mesothelioma cases may be important in determining prognosis.

Key words: Mesothelioma; c-Met; PDGFR-alpha; mTOR
INTRODUCTION

Malignant mesothelioma is a tumour with an aggressive course that originates in serous surfaces such as the pleura, peritoneum, tunica vaginalis and pericardium, respectively according to frequency (1). The most important cause of pleural mesothelioma is a history of exposure to asbestos (2). Although asbestos is a significant etiological factor for the development of peritoneal mesothelioma, a higher cumulative exposure is required compared to pleural mesothelioma (3). In the pathogenesis of mesothelioma, there are several molecules and signal transmission pathways that are responsible for cell growth, proliferation, motility, angiogenesis, invasion and metastasis. In this study, we examined that c-Met, EGFR (epidermal growth factor receptor), PTEN (phosphatase and tensin homologue), and PDGFR-alfa (platelet derived growth factor receptor alpha) molecules and the PI3K/AKT/mTOR signal transmission pathway. While some studies have suggested that the expression levels of these molecules could have an effect on survival (4-7); some studies have found no significant difference in survival between negative and positive groups according to the expression level (8,9). The primary end point of this study was to examine the relationship of progression free survival (PFS) and overall survival (OS) with the level of these molecules in the tumour tissue of pleural and peritoneal mesothelioma cases. Secondary end points were the association between PFS and OS with the clinicopathological parameters and the treatments given.

MATERIALS and METHODS

Fifty-three cases with histologically diagnosed malignant mesothelioma were included in the study. The cases treated and followed up between 2005 and 2016 in the medical oncology department were separated into two groups as pleural and peritoneal mesothelioma. The effect of the levels of c-Met, EGFR, PTEN, PDGFR-alfa, PI3K/AKT and mTOR expression on OS and PFS was examined. The demographic characteristics, exposure to asbestos, smoking status, histopathological type, localisation, and treatments applied were evaluated. Poor performance (Eastern Cooperative Oncology Group performance-status score ≥ 2) was accepted in all the groups as a reason for not administering chemotherapy.

Study Design

Biopsy (surgical or not) samples of the all patients were fixed in 10% formaldehyde. Sections 5 microns in thickness were cut from the embedded tissue into paraffin blocks. With an ultraView UniversalDAB Detection kit (Ventana, 760-500) in an automatic Ventana BenchMark XT immunohistochemical staining device, the following antibodies were applied: Rabbit Anti- Human mTOR Polyclonal Antibody (E18594, Spring Bioscience), Rabbit Anti-Human c-Met Polyclonal Antibody (E10612, Spring Bioscience), Rabbit Anti-PTEN (SP218) Monoclonal Antibody (M5180, Spring Bioscience), PDGFR alpha Polyclonal Antibody (PA5-16742, Thermo Scientific), CONFIRM anti-Epidermal Growth Factor Receptor (3C6) Primary Antibody (790-2988, Ventana), Phospho-Akt (Ser473)
(736E11) Rabbit mAb (3787, Cell Signaling). The results were evaluated under a Nikon Eclipse E200 light microscope. Although PDGFR-alpha was generally cytoplasmic stained, cytoplasmic and membranous staining was accepted positive as previously described (10). EGFR is based on a membranous staining pattern and PTEN is detected in the cytoplasm (5). For PI3K/AKT and mTOR pathway the percentage of stained tumor cells was scored in a whole section, and the average percentage and intensity of tumor cell staining was calculated as a semiquantitative histo score method as described previously (11). For c-Met, stain localization to the cell cytoplasm, cytoplasmic membrane, or both was recorded. For all biomarkers grading was made according to the intensity and ratio of staining as negative (0), weak (+1), moderate (+2) and strong (+3). Evaluation was made according to the ratio of stained cells as negative (0), 0%-20% weak (+1), 20%-60% moderate (+2) and 60%-100% strong (+3) (12,13). Comparisons were made between the (2+, 3+) groups and and the (0, 1+) groups.

### Statistical Analysis

Statistical analyses of the data were made using IBM SPSS vn 20.0 software. Descriptive statistics were shown as mean, median, standard deviation, minimum and maximum values as appropriate. Progression-free survival was evaluated as the time from diagnosis to recurrence, metastasis or death from other reasons with no development of recurrence. Overall survival was calculated from diagnosis of malignancy until death due to any cause. All patients died when the study was performed. Survival analysis was performed using Kaplan-Meier curves and the significance was verified by a log-rank test. All p values were determined by two-sided tests and p values < 0.05 were considered significant. (2+, 3+) groups were defined as high expression and (0, 1+) groups were defined as low expression.

### RESULTS

The study included 53 patients who presented at the medical oncology department and were diagnosed with malignant mesothelioma. The demographic and clinical characteristics of the patients are shown in Table 1. Occupation was recorded as housewife in 25 (47.2%) cases, farmer in 14 (26.4%), and various other occupations in the other 14 cases. The localisation of the tumour was in the pleura in 39 (73.6%) patients and in the peritoneum in 14 (26.4%). No significant difference was determined between the two groups in respect of OS, as median 15 months in the pleural cases and 12 months in the peritoneal cases (p= 0.559). And also no statistically significant difference was determined between the two groups in respect of PFS, as median 10 months in the pleural cases and 6 months in the peritoneal group (p= 0.432).

In 24 (45.3%) of all patients there was a history of asbestos exposure, and when the effect on OS was examined, in the group with pleural mesothelioma the OS was determined to be 15 months in those with asbestos exposure and 18 months in the group not exposed to asbestos (p= 0.367). In the group with peritoneal mesothelioma, OS was determined as 12 months in those with asbestos exposure and 13 months in those without (p= 0.501). Of the total patients, 22 (41.5%) smoked and 31 (58.5%) did not smoke. Of the pleural mesothelioma group, OS was 12 months for those who smoked and 18 months for the non-smokers (p= 0.657). Of the peritoneal mesothelioma group, OS was 8 months for those who smoked and 12 months for the non-smokers (p= 0.844).

### Surgery and Survival

The surgical treatment methods applied to the 39 pleural mesothelioma cases with no metastasis were recorded as partial decortication in 7 (17.9%), total

---

**Table 1. Demographic and clinical characteristics of the patients**

| Parameter              | Number (%) |
|------------------------|------------|
| **Gender**             |            |
| Female                 | 27 (50.9)  |
| Male                   | 26 (49.1)  |
| **Median age (min-max) (years)** |            |
| Pleural                | 39 (73.6)  |
| Peritoneal             | 14 (26.4)  |
| **Histological type**  |            |
| Epithelial             | 41 (77.4)  |
| Sarcomatous            | 2 (3.8)    |
| Biphasic               | 10 (18.9)  |
| **Asbestos exposure**  |            |
| Positive               | 24 (45.3)  |
| Negative               | 29 (54.7)  |
| **Cigarette smoking**  |            |
| Positive               | 22 (41.5)  |
| Negative               | 31 (58.5)  |
decortication in 10 (25.6%) and extrapleural pneumonectomy in 10 (25.6%). No surgery was applied to the 12 (30.8%) patients with metastatic disease. In the pleural mesothelioma patients, OS was determined as 6 months in patients not applied with surgery, 9 months in those applied with partial decortication, 24 months for total decortication, and 29 months for extrapleural pneumonectomy. Of the 14 malignant peritoneal mesothelioma cases in the study, omentectomy was applied to 6 (42.9%) patients. OS was determined as 12 months in those applied with omentectomy and 8 months in those who did not undergo surgery.

**Chemotherapy and Survival**

First line chemotherapy was administered to 27 (69.2%) of the cases with pleural mesothelioma. Pemetrexed + cisplatin was administered to 21 (77.8%) cases, gemcitabine + cisplatin to 4 (14.8%) and pemetrexed + carboplatin to 2 (7.4%). OS was 18 months for those who received first line chemotherapy and 3 months for those who did not. The difference between the groups was statistically significant (p= 0.004). Second line chemotherapy was administered to 17 (43.6%) of the pleural group. Vinorelbine was administered as the single agent to 1 (5.9%) patient, gemcitabine + vinorelbine to 1 (5.9%) patient, cisplatin + pemetrexed to 2 (11.8%) patients, gemcitabine + carboplatin to 2 (11.8%) patients, and gemcitabine + cisplatin to the remaining 11 (64.7%) patients. OS was determined as 29 months for those who received second line chemotherapy and 7 months for those who did not. The difference between the groups was statistically significant (p< 0.001).

In the peritoneal mesothelioma group, 10 (71.4%) of 14 patients received first line chemotherapy. Of these, 9 were administered pemetrexed + cisplatin, and 1 with pemetrexed + carboplatin. OS was determined as median 15 months for those who received first line chemotherapy and 1 month for those who did not. The difference between the groups was statistically significant (p= 0.001). Second line chemotherapy was administered to 7 patients in the peritoneal group, as cisplatin + pemetrexed to 3 (42.8%), and gemcitabine + cisplatin to the remaining 4 patients. OS was determined as median 18 months for those who received second line chemotherapy and 4 months for those who did not. The difference between the groups was statistically significant (p= 0.014).

**Radiotherapy**

In 8 (20.5%) of the pleural mesothelioma cases, palliative radiotherapy was applied for the relief of pain and shortness of breath. Survival analysis was not examined in respect of palliative radiotherapy. OS and PFS results of the pleural and peritoneal mesothelioma cases according to c-Met, EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expressions and also frequencies of the positivity of the expression are shown in Tables 2 and 3.

| Table 2. OS and PFS rates of the patients with pleural mesothelioma according to expression levels |
|-----------------------------------------------|------------------|-------------------|-------------------|---------------------|------------------|-------------------|
| **Marker** | **Expression level** | **No of patients (%)** | **Median OS (months)** | **p value (OS)** | **Median PFS (months)** | **p value (PFS)** |
| -------- | ----------------- |———————————|———————————|———————————|———————————|———————————|
| c-Met | 0, +1 | 11 (28.2) | 10 | 0.46 | 6 | 0.26 |
| | +2, +3 | 28 (71.8) | 18 | | |
| EGFR | 0, +1 | 8 (20.5) | 9 | 0.28 | 6 | 0.34 |
| | +2, +3 | 31 (79.5) | 18 | | |
| PTEN | 0, +1 | 1 (2.6) | 32 | 0.70 | 12 | 0.91 |
| | +2, +3 | 38 (97.4) | 15 | | |
| PDGFR-alpha | 0, +1 | 30 (76.9) | 18 | 0.003 | 11 | 0.02 |
| | +2, +3 | 9 (23.1) | 8 | | |
| PI3K/AKT | 0 | 32 (82.1) | 15 | 0.075 | 10 | 0.18 |
| | +1 | 7 (17.9) | 38 | | |
| mTOR | 0, +1 | 8 (20.5) | 9 | 0.67 | 6 | 0.32 |
| | +2, +3 | 31 (79.5) | 15 | | |

OS: Overall survival, PFS: Progression free survival.
DISCUSSION

In a retrospective study of biopsy samples of 341 cases with pleural mesothelioma, Opitz et al. reported that immunohistochemically, PTEN expression of 62% of patients was negative, and the survival of all the positive groups (weak, moderate, strong staining) was better than that of the negative group (14). Agarwal et al. showed negative PTEN expression in 26.7% of 86 cases with pleural mesothelioma, and unlike the previous study, there was no statistically significant difference between the groups in respect of survival (15). In the current study, PTEN expression negativity was determined in only 2.6% of the pleural mesothelioma cases, and almost all the cases (97.4%) were stained (2+, 3+). When PTEN expression was examined as two groups (0, 1+ vs. 2+, 3+), no statistically significant difference was determined in respect of OS. The same was true for PFS in pleural mesothelioma and for both OS and PFS in peritoneal mesothelioma, which could be attributed to the limited number of patients and that the vast majority were negative.

PTEN, which is of key importance between anabolic and catabolic metabolisms, is an intracellular serin-treonin protein kinase, located at a central point in the intracellular signal cascade (19). As mTOR is a kinase with a key function in the downward-flowing PI3K/AKT pathway, its inhibition is considered to be an important potential therapeutic target (20). In the current study, while no difference was seen in OS and PFS between the (0; 1+) and (2+; 3+) groups of mTOR expression in the pleural mesothelioma cases, in the peritoneal cases, OS of the (0; 1+) mTOR expression group was seen to be statistically significantly longer than that of the (2+; 3+) group.

In the immunohistochemical examination of biopsy samples of 71 patients with malignant pleural mesothelioma, Gaafar et al. reported the median overall survival to be 12 months in the group with positive EGFR expression and 8 months in the negative group, but the difference was not evaluated as statistically significant (21). There is known to be an increase in the EGFR expression of the majority of peritoneal mesothelioma cases. From this starting

| Marker | Expression level | No of patients (%) | Median OS (months) | p value (OS) | Median PFS (months) | p value (PFS) |
|--------|-----------------|--------------------|-------------------|-------------|--------------------|-------------|
| c-Met  | 0, +1           | 2 (14.3)           | 1                 | 0.005       | 1                  | 0.005       |
|        | +2, +3          | 12 (85.7)          | 13                | 0.74        | 6                  | 0.91        |
|        | 0, +1           | 3 (21.4)           | 12                | 0.74        | 6                  | 0.91        |
|        | +2, +3          | 11 (78.6)          | 13                | 0.74        | 6                  | 0.91        |
| EGFR   | 0, +1           | 1 (7.1)            | 1                 | 0.056       | 1                  | 0.056       |
|        | +2, +3          | 13 (92.9)          | 13                | 0.056       | 6                  | 0.056       |
|        | 0, +1           | 8 (57.1)           | 3                 | 0.37        | 3                  | 0.36        |
|        | +2, +3          | 6 (42.9)           | 13                | 0.37        | 3                  | 0.36        |
| PDGFR-alpha | 0, +1     | 13 (92.9)          | 13                | 0.54        | 6                  | 0.60        |
|        | +1, +2          | 1 (7.1)            | 12                | 0.54        | 6                  | 0.60        |
| PI3K/AKT| 0               | 2 (14.3)           | 1                 | 0.047       | 1                  | 0.047       |
|        | 0, +1           | 12 (85.7)          | 13                | 0.047       | 6                  | 0.047       |
|        | +2, +3          | 13 (92.9)          | 13                | 0.047       | 6                  | 0.047       |
| mTOR   | 0, +1           | 13 (92.9)          | 13                | 0.54        | 6                  | 0.60        |
|        | +2, +3          | 6 (42.9)           | 13                | 0.54        | 6                  | 0.60        |

OS: Overall survival, PFS: Progression free survival.
point, a Phase II study showed that the use of EGFR inhibitors was of no significant clinical benefit (22). In the current study, no statistically significant difference was determined in OS or PFS in both the pleural and peritoneal malignant mesothelioma cases when examined as two groups of low (0; 1+) and high (2+; 3+) EGFR expression.

c-Met is a receptor tyrosine kinase encoded by MET proto-oncogene located in chromosome 7q31 region. In comparison with normal pleura, it has been shown to be expressed more in pleural mesothelioma tissues (23). In the current study, no statistically significant difference was determined in OS or PFS in the pleural mesothelioma cases when examined as two groups of low (0; 1+) and high (2+; 3+) c-Met expression. In the peritoneal mesothelioma cases, OS was seen to be statistically significantly longer in the high (2+; 3+) c-Met expression group than in the low expression (0; 1+) group, and this was similar in respect of PFS. Progress in cancer biology has led to an increasing discovery of oncogenic alterations of the platelet-derived growth factor receptors (PDGFRs) in cancers. In addition, their overexpression in numerous cancers invariably makes PDGFRs and platelet-derived growth factors (PDGFs) prognostic and treatment markers in some cancers (24). In the current study, OS was seen to be statistically significantly longer in the low (0+; 1+) PDGFRα expression group than in the high (2+; 3+) expression group pleural mesothelioma cases, and this was similar in respect of PFS. No statistically significant difference was seen in the OS and PFS between the low (0; 1+) and high (2+; 3+) expression groups of PDGFR-alpha in the peritoneal mesothelioma cases.

OS in malignant pleural mesothelioma in the literature has been shown to vary between 5 and 22 months and in the current study, OS was determined as 15.8 months. OS of patients with peritoneal mesothelioma was 12 months. OS and PFS in all the patient groups was seen to be better in the chemotherapy group.

CONCLUSION

The results of this study suggest that the examination of c-Met, PDGFR-alpha, and mTOR expressions in mesothelioma biopsy and operating materials could be important for the determination of prognosis. There is a need for further more extensive studies on this subject.

CONFLICT of INTEREST

No conflict of interest declared by the authors.

AUTHORSHIP CONTRIBUTIONS

Concept/Design: MT, MB, İOK, DG, EB

Analysis/Interpretation: MT, İOK, DG, EB

Data Acquisition: MT, MB

Writting: MT, MB, İOK

Critical Revision: MT, MB, İOK

Final Approval: All of authors.

REFERENCES

1. Tischoff I, Tannapfel A. Mesothelioma. Pathologe 2017;38:547-60.
2. Lemen RA. Mesothelioma from asbestos exposures: epidemiologic patterns and impact in the United States. J Toxicol Environ Health B Crit Rev 2016;19:250-65.
3. Mensi C, Mendola M, Dallari B, Sokooti M, Tabibi R, Riboldi L, et al. Differences between peritoneal and pleural mesothelioma in Lombardy, Italy. Cancer Epidemiol 2017;51:68-73.
4. Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, et al. c-Met expression and MET amplification in malignant pleural mesothelioma. Ann Diagn Pathol 2016;23:1-7.
5. Liang Y, Zheng G, Yin W, Song H, Li C, Tian L, et al. Significance of EGFR and PTEN expression and PLR and NLR for predicting the prognosis of epithelioid malignant peritoneal mesothelioma. Gastroenterol Res Pract 2019;2019:7103915.
6. Yap TA, Aerts JC, Papat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 2017;17:475-88.
7. Opitz I, Soltermann A, Abacheerli M, Hinterberger M, Probst-Hensch N, Stahel R, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008;33:502-6.
8. Metheny-Barlow LJ, Flynn B, van Gijssel HE, Marrogi A, Gerwin BI. Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo. Am J Respir Cell Mol Biol 2001;24:694-702.
9. Ramos-Nino ME, Vianale G, Sabo-Attwood T, Mutti L, Porta C, Heintz N, et al. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther 2005;4:835-42.
10. Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, et al. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am J Pathol 2011;179:1483-93.
11. Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Martí A, Zugazagoitia J, et al. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Lung Cancer 2016;96:1-6.

12. Levallet G, Vaise-Lestreet M, Le Stang N, Ilg AG, Brochard P, Astoul P, et al. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma, a series of 157 cases from the MESOPATH Group. J Thorac Oncol 2012;7:599-606.

13. Dziadziszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, Konopa K, et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012;7:340-7.

14. Opitz I, Soltermann A, Abaecherli M. PTEN expression is a strong predictor of survival in mesothelioma patients. European Journal of Cardio-thoracic Surgery 2008;33:501-5.

15. Agarwal V, Campbell A, Beaumont KL. PTEN protein expression in malignant pleural mesothelioma. Tumor Biol 2013;34:847-51.

16. Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2009;2:181-8.

17. Alomare DA, You H, Xia G, Ramos-Nino ME, Skele KL, De Rienzo A, et al. Human and mouse mesotheliomas exhibit elevated akt/pkb activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005;24:6080-9.

18. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, et al. Phase 2 study of erlotinib in patients with malignant pleural mesothelioma: a southwest oncology group study. J Clin Oncol 2007;25:2406-13.

19. Faire S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev 2006;5:671-8.

20. Kucukoner M, Isikdogan A. mTOR signaling pathway and mTOR inhibitors in the treatment of cancer. Dicle Medical Journal 2013;40:156-60.

21. Gaafar R, Bahnassy A, AbdelSalam I, Kamel MM, Helal A, Abdel-Hamid A, et al. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 2010;70:43-50.

22. Govindan R, Kratzke RA, Hernden JF, Niehans GA, Vollmer R, Watson D, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005;11:23004.

23. Zimmerman RL, Fogt F. Evaluation of the c-Met immunostain to detect malignant cells in body cavity effusions. Oncol Rep 2001;8:1347-50.

24. Appiah-Kubi K, Wang Y, Qian H, Wu M, Yao X, Wu Y, et al. Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers. Tumour Biol 2016;37:10053-66.

25. Soeberg MJ, Creighton N, Currow DC, Young JM, van Zandwijk N. Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009. Aust N Z J Public Health 2016;40:255-62.

26. Alexander HR Jr, Li CY, Kennedy TJ. Current management and future opportunities for peritoneal metastases: peritoneal mesothelioma. Ann Surg Oncol 2018;25:2159-64.